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C1q/tumor necrosis factor (TNF)-related protein-3 (CTRP3) is a recently discovered
adiponectin paralog with established metabolic regulatory properties. However, the
role of CTRP3 in intracerebral hemorrhage (ICH) is still mostly unresolved. The aim
of the present report was to explore the possible neuroprotective effect of CTRP3 in
an ICH rat model and to elucidate the fundamental mechanisms. ICH was induced
in rats by intracerebral infusion of autologous arterial blood. The effects of exogenous
CTRP3 (recombinant or lentivirus CTRP3) on brain injury were explored on day 7.
Treatment with CTRP3 reduced brain edema, protected against disruption of the
blood-brain barrier (BBB), improved neurological functions and promoted angiogenesis.
Furthermore, CTRP3 greatly intensified phosphorylation of AMP-activated protein kinase
(AMPK) in addition to expression of hypoxia inducing factor-1α (HIF-1α) and vascular
endothelial growth factor (VEGF). Finally, the protective effects of CTRP3 could be
blocked by either AMPK or VEGF inhibitors. Our findings give the first evidence that
CTRP3 is a new proangiogenic and neuroprotective adipokine, which may exert its
protective effects at least partly through an AMPK/HIF-1α/ VEGF-dependent pathway,
and suggest that CTRP3 may provide a new therapeutic strategy for ICH.
Keywords: CTRP3, intracerebral hemorrhage, brain edema, blood-brain barrier disruption, neuroprotection,
angiogenesis
INTRODUCTION
Intracerebral hemorrhage (ICH) is responsible for about 10–15% of stroke cases. Nevertheless,
it is the most alarming type due to its large fatality rate and poor functional outcome (Qureshi
et al., 2009; Manaenko et al., 2013). ICH results from rupture of blood vessels in the brain.
The quick release of blood into the parenchyma leads to substantial mechanical damage
that may only be somewhat ameliorated by limiting hematoma volume (Mayer et al., 2008).
Meanwhile, secondary damage ensues due to toxic effects of released blood components, such
as thrombin, as well as erythrocyte rupture (for example, iron-catalyzed free radical reactions).
These events, including disruption of the blood-brain barrier (BBB) as well as growth of edema
and inflammation, are currently therapeutic targets for ICH (Fingas et al., 2009; Keep et al.,
2012).
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Therapies such as angiogenesis have been suggested for
ICH. Growing evidence suggests that after ICH, angiogenesis is
upregulated in damaged brain tissue of the peri-hematoma area,
leading to compensatory cerebral vascular network remodeling
(Teng et al., 2008; Lei et al., 2015). Past reports showed that many
angiogenic aspects could ease ischemic brain injury, elevate focal
blood flow and enhance neurological results, which indicate that
recently formed microvessels are indeed functional (Hao et al.,
2011; Shen et al., 2013). Blood vessels are a significant scaffolding
factor that assist with the migration of neurons to damaged
brain areas and supply trophic material to new neurons (Kojima
et al., 2010; Lei et al., 2013). The molecules that encourage
neurogenesis and angiogenesis after brain injuries (e.g., ICH) are
still unidentified.
Recently, a highly conserved family of adiponectin paralogs,
C1q/tumor necrosis factor(TNF)-related proteins (CTRPs), was
identified. Each of the 15 known members (CTRP1–CTRP15)
is made up of four separate domains including an N-terminal
signal peptide, a short variable domain, a collagen-like domain,
and a C-terminal C1q-like globular domain (Ahima et al.,
2006). Both CTRPs and adiponectin are a part of the C1q/TNF
protein superfamily, which proceeds to increase in size as
more C1q domain proteins are identified (Yi et al., 2012). The
CTRP family members exhibit broadly diverse physiological
functions, including regulation of metabolism, protection against
endothelial dysfunction and angiogenesis.
CTRP3 is ubiquitously expressed in adipocytes,
cartilagocytes, monocytes, fibroblasts, placenta, osteosarcoma,
chondroblastoma, giant cell tumor, colon, small intestine,
pancreas, kidney, thymus, ovary and in brain (Schaffler and
Buechler, 2012). Most importantly, CTRP3 is the only one
whose biological functions have been identified (Peterson
et al., 2010). It was found that CTRP3 can encourage in vitro
endothelial cell proliferation and migration (Akiyama et al.,
2007). But, the role of CTRP3 in promoting angiogenesis
in ICH-induced brain injury is not yet known. Further,
whether or not CTRP3, an important member of the most
recently discovered adipokine family, works as a mediator or
inhibitor of ICH has not been studied previously. Therefore,
the goals of this research were: (1) to investigate the effects
of exogenous CTRP3 in an ICH rat model; (2) to determine
whether CTRP3 administration promotes angiogenesis after




All animal studies were given approval by the Chongqing
Medical University Biomedical Ethics Committee. All
experimental procedures were done in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals. All efforts were made to minimize the
number of animals used and their suffering. A total of 115 adult
male Sprague-Dawley rats (60–80 d old, 240–300 g) were used
for the in vivo study.
Establishment of Intracerebral
Hemorrhage Model
ICH was induced by an intrastriatal blood infusion method as
described previously (Ni et al., 2015). Briefly, rats were deeply
anesthetized with chloral hydrate (350 mg/kg, intraperitoneal
injection) and placed in a stereotaxic frame (Kopf Instruments,
Tujunga, CA, USA). After removing the hair and cleaning the
scalp, the skin was incised. A burr hole was drilled 0.2 mm
anterior and 3.0 mm lateral right of bregma. Whole blood
(50 µL), which was drawn from the femoral artery, was infused
manually over 10 min via a 26 G needle inserted into the striatum
at a depth of 5.8 mm below the surface of the skull. After 10 min,
the needle was steadily taken out for 5 min followed by the
sealing of the burr hole with a sterilized medical bone wax. The
wound was cleaned, and the scalp was sutured. The animals were
given time to heal in their cages. During the recovery period, the
animals had unlimited access to nourishment.
In vivo Experiments
Rats were given free access to food and water in an optimal
environment preceding the operation. Three in vivo experiments
were performed as described below.
Experiment 1
Adult rats were split at random into the following four
groups: sham-operated (sham) group, ICH group, ICH + vehicle
group and ICH + recombinant CTRP3 (rCTRP3, Chimerigen,
USA) group. rCTRP3 was injected intracerebroventricularly
(80 µg/kg) 30 min after ICH and then three times per
week until the animals were killed. Neurological deficits
(assessed by a modified Garcia test, beam walking test and
wire hanging test), hematoma volume, BBB integrity and
brain edema were measured 7 days after ICH, and samples
for western blot, qRT-PCR and immunohistochemistry were
collected.
Experiment 2
Adult rats were split at random into the following four groups:
sham-operated (sham) group, ICH group, ICH + null vector
control (Lenti.null) group, ICH + lentivirus overexpression of
CTRP3 (Lenti.CTRP3) group. Fourteen days after Lenti.CTRP3
intracerebroventricular injection, the rats underwent ICH.
Neurological deficits, hematoma volume, BBB integrity and
brain edema were measured 7 days after ICH, and samples
for western blot, qRT-PCR and immunohistochemistry were
collected.
Experiment 3
Adult rats were split at random into the following four
groups: ICH group, ICH + rCTRP3 group, ICH + rCTRP3 +
compound C (Com.C) group (AMP-activated protein kinase
(AMPK) axis inhibitor, 20 µg/kg, intracerebroventricular
injection, 3 times per week), and ICH + rCTRP3 + CBO-
P11 (CBO) group (vascular endothelial growth factor (VEGF)
inhibitor 40 µg/kg, intracerebroventricular injection, 3 times
per week). Neurological deficits and BBB integrity were
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measured 7 days after ICH, and samples for western blot and
immunohistochemistry were collected.
Lentivirus-CTRP3 Gene Transfer in the Rat
Brain
Adult rats were anesthetized with chloral hydrate (350 mg/kg
intraperitoneal injection) and then placed in a Kopf stereotactic
frame. A burr hole was bored in the pericranium 0.9 mm lateral
to the sagittal suture and 1.9 mm posterior to the coronal suture.
A 10 µL microinjection pump (WPI Inc., Sarasota, FL, USA)
was stereotactically inserted 3.5 mm deeper into the cortex. A
5 µL viral suspension consisting of 1 × 109 genomic copies of
the lentivirus-CTRP3 (Lenti-CTRP3) gene, which was injected
ipsilaterally into the right lateral cerebral ventricle at a rate of
0.2 µL/min. The needle was taken out after 15 min of injection.
The animals then were allowed to heal and brought back to their
cages.
Behavioral Assessment
Behavioral functions were measured using a modified Garcia
test, beam walking test, and wire hanging test 7 days after
ICH in a blind fashion (Chen et al., 2013). In the modified
Garcia test, rats were given a score of 0–18. The scoring
system consisted of six tests, with possible scores of 0–3
(0 = worst; 3 = best). The minimum score was 0 and
the maximum was 18. Beam walking and wire hanging tests
utilized bridges (550 cm wire or 590 cm beam) between
two platforms on which the rats were placed in the center.
Rats were assessed according to six criteria that described if
the animal could reach the platform and use its limbs in
a symmetrical manner and were then given a score of 0–5
(normal). The average of three trials per test for each animal was
calculated.
BBB Permeability
Seven days after ICH, rats were intravenously injected with
2% Evans blue dye (4 mL/kg; Sigma-Aldrich, St. Louis, MO,
USA). Three hours later, the amount of extravasated Evans blue
dye in the hemorrhagic brain hemispheres was evaluated by
spectrophotometry (Thermo Scientific, MA, USA) at 620 nm
(Cai et al., 2015).
Brain Water Content
Seven days after ICH, the cerebral hemisphere was cut into
4-mm thick blocks around the needle track. Brain tissues were
immediately weighed using an analytical balance and heated at
100◦C for 24 h to obtain the dry weight. The water content
was calculated using the following formula: (wet weight– dry
weight)/wet weight× 100%.
Hematoma Volume
Hematoma volume was evaluated using a spectrophotometric
hemoglobin assay 7 days after the ICH operation (Ma et al.,
2014).
Western Blot Analysis
Total protein was extracted from the peri-hematoma area of the
rat striatum using cell lysis buffer supplemented with proteinase
and phosphatase inhibitors. Cell lysates were split by 10% SDS-
PAGE and transferred to polyvinylidene fluoride membranes.
Then, the membranes were blocked in 5% non-fat milk TBST
buffer for 1.5 h at room temperature. The membranes were
incubated in primary antibody overnight at 4◦C and in secondary
antibody for 1 h at room temperature. Dilutions for primary
antibodies were the following: anti-vascular endothelial growth
factor (VEGFA; 1:1000, Abcam, Cambridge, MA, USA), anti-
hypoxia inducing factor-1α (HIF-1α; 1:500, Abcam, Cambridge,
MA, USA), and anti-AMPK (phospho-thr172; 1:500, Bioworld,
Dublin, OH, USA). The secondary antibody was diluted
1:5000 (Sangon Biotech, Shanghai, Co., Ltd.). The density
of bands was detected using an imaging densitometer (Bio-
Rad, Foster City, CA, USA), and the gray value of bands
was quantified using Quantity One 1-D analysis software
(Bio-Rad).
qRT-PCR
Total RNA was removed with RNAiso Plus (TaKaRa
Biotechnology, Dalian, China) using the manufacturer’s
instructions. Reverse transcription was done with a cDNA
FIGURE 1 | Effects of CTRP3 treatment on brain water content 7 days
after ICH. (A) Brain water content in ipsilateral (Ipsi) and contralateral (Contra)
hemispheres 7 days after ICH in rats treated with rCTRP3. (B) Brain water
content in ipsilateral (Ipsi) and contralateral (Contra) hemispheres 7 days after
ICH in rats treated with Lenti-CTRP3. Values are mean ± SEM. n = 8 per
group. ∗p < 0.05 vs. sham; #p < 0.05 vs. vehicle or Lenti.null. CTRP3,
C1q/tumor necrosis factor-related protein-3; rCTRP3, recombinant CTRP3;
Lenti.CTRP3, Lentivirus overexpression of CTRP3; ICH, intracerebral
hemorrhage.
TABLE 1 | Primers used in qRT-PCR.
Gene product Forward primer Reverse primer Fragment size (bp)
CTRP3 5′-ATGGAGGTGAGCAGAAGAGC-3′ 5′CACAGTCCCCGTTTTAGCAT-3′ 126
HIF-1α 5′-CTCCCTTTTTCAAGCAGCAG-3′ 5′GCTCCATTCCATCCTGTTCA-3′ 125
VEGFA 5′-CGTCCTGTGTGCCCCTAAT-3′ 5′TGGCTTTGGTGAGGTTTGAT-3′ 121
β-actin 5′-TGTTTGAGACCTTCAACACC-3′ 5′-CGCTCATTGCCGATAGTGAT-3′ 207
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synthesis kit (TaKaRa Biotechnology). Real-time PCR
reactions were performed with TaKaRa SYBR Premix Ex
Taq II (TliRnaseH Plus, TaKaRa Biotechnology) on a PCR
amplifier (CFX-96 Content Real-time System). Primers (Sangon
Biotech) are recorded in Table 1.
Immunohistochemistry
Rats were killed 7 days after ICH induction by intraperitoneal
injection of chloral hydrate. Immunohistochemistry was
performed as previously described (Lei et al., 2013; Lapi et al.,
2015). The primary antibody used was rabbit anti-rat CD31
(1:100, Abcam, USA). Total vessel densities were computed by
counting 4 areas in 3 sections through the stroke region for
each animal. Sections were stained with antibody against new
vessel marker CD31; positive staining appeared brown. Standard
quantitation was done as percent CD31-positive in the region
bordering the hematoma.
FIGURE 2 | Effects of CTRP3 treatment on neurological functions 7
days after ICH. All animals after ICH showed significant neurological deficits
based on performance on the modified Garcia (A), beam balance (B) and wire
hanging (C) tests. Rats treated with rCTRP3 showed reduced neurological
deficits in all three tests. Treatment with Lenti-CTRP3 starting 2 weeks before
induction of ICH showed a tendency to ameliorate neurological deficits
(D–F). Values are mean ± SEM. n = 9 per group. ∗p < 0.05 vs. sham;
∗∗p < 0.01 vs. sham; #p < 0.05 vs. vehicle or Lenti.null. CTRP3, C1q/tumor
necrosis factor-related protein-3; rCTRP3, recombinant CTRP3; Lenti-CTRP3,
Lentivirus overexpression of CTRP3; ICH, intracerebral hemorrhage.
Statistical Analysis
All data are given as mean± S.E.M. One-way analysis of variance
(ANOVA) followed by Student’s t test was utilized to collate
outcomes among all groups. The SPSS 17.0 software package was
utilized to do all statistics. P < 0.05 was considered statistically
significant.
RESULTS
CTRP3 Reduced Brain Edema and
Improved Functional Outcomes after ICH
Quantification of brain water content showed that ICH rats
had significantly greater edema in the ipsilateral hemisphere
than sham-operated rats (Figure 1A). Brain edema in the
ipsilateral hemisphere was significantly less in rCTRP3-
treated rats than in vehicle-treated rats (Figure 1A). In
the contralateral hemisphere, rCTRP3 failed to affect
brain water content (Figure 1A). Subsequently, we tested
functional outcomes using a battery of behavioral tests in
rats treated with rCTRP3 or vehicle. Neurological deficits
were significantly more severe in all ICH vs. sham animals
7 days after ICH as tested by the modified Garcia test
(Figure 2A), wire hanging test (Figure 2B), and beam balance
test (Figure 2C). A statistically significant advancement
was seen in all three neurobehavioral tests after rCTRP3
treatment.
Similarly, Lenti.CTRP3 treatment decreased brain water
content in ICH rats (Figure 1B). Statistically significant
neurological shortfalls were observed in all ICH vs. sham
animals 7 days after ICH. Treatment with Lenti-CTRP3
tended to ameliorate neurological deficits 7 days after ICH
(Figures 2D–F). Both the rCTRP3 and Lenti.CTRP3 treatments
were effective.
FIGURE 3 | Effects of CTRP3 treatment on ICH-induced blood-brain
barrier (BBB) damage 7 days after ICH. (A) Quantification of Evans blue
dye extravasation (blue staining) in the ipsilateral (Ipsi) and contralateral
(Contra) hemispheres 7 days after ICH in rats treated with rCTRP3.
(B) Quantification of Evans blue dye extravasation (blue staining) in ipsilateral
(Ipsi) and contralateral (Contra) hemispheres 7 days after ICH in rats treated
with Lenti-CTRP3. Values are mean ± SEM. n = 6 per group. ∗∗p < 0.01 vs.
sham; #p < 0.05 vs. vehicle or Lenti.null. CTRP3, C1q/tumor necrosis
factor-related protein-3; rCTRP3, recombinant CTRP3; Lenti-CTRP3,
Lentivirus overexpression of CTRP3; ICH, intracerebral hemorrhage.
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FIGURE 4 | CTRP3 encourages angiogenesis in the hematoma border zone 7 days after ICH. (A) Capillary density computed by immunohistochemical
staining for CD31 (brown) in the perifocal region in ICH (b), rCTRP3 (c) and Lenti-CTRP3 (d) 7 days after ICH. A control brain section demonstrates a normal
distribution of microvessels in the same region (a). Bar = 100 µm. (B) Bar graph showing the number of brown stained capillaries 7 days after ICH. Values are
mean ± SEM. n = 5 per group. ∗p < 0.05 vs. sham; ∗∗p < 0.01 vs. sham; #p < 0.05 vs. ICH. CTRP3, C1q/tumor necrosis factor-related protein-3; rCTRP3,
recombinant CTRP3; Lenti-CTRP3, Lentivirus overexpression of CTRP3; ICH, intracerebral hemorrhage; CD31, platelet endothelial cell adhesion molecule-1.
FIGURE 5 | CTRP3 upregulates pAMPK/HIF-1α/vascular endothelial growth factor (VEGF) axis protein expression in the hematoma border zone 7
days after ICH. (A) Western blot analysis of the effect of rCTRP3 on CTRP3, phosphorylated (p) AMP-activated protein kinase (AMPK; Thr172)/AMPK, HIF-1α and
VEGF-A. (B–E) Representative ratios of CTRP3, p-AMPK, HIF-1α and VEGF-A protein expression. (F) Western blot analysis of the effect of Lenti-CTRP3 on CTRP3,
phosphorylated (p) AMPK (Thr172)/AMPK, HIF-1α and VEGF-A. (G–J) Representative ratios of CTRP3, p-AMPK, HIF-1α and VEGF-A protein expression. Values are
mean ± SEM. n = 4 per group. ∗p < 0.05 vs. sham; ##p < 0.01 vs. vehicle or Lenti.null. CTRP3, C1q/tumor necrosis factor-related protein-3; rCTRP3, recombinant
CTRP3; Lenti-CTRP3, Lentivirus overexpression of CTRP3; ICH, intracerebral hemorrhage.
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CTRP3 Reduced Disruption of the BBB
We measured BBB permeability by Evans blue extravasation
in ICH rats. Significant accumulation of Evans Blue stain was
seen in the ipsilateral hemisphere of ICH in comparison to
sham animals (Figure 3A). Treatment with rCTRP3 significantly
reduced the quantity of stain in the ipsilateral hemisphere
in comparison to the vehicle 7 days after ICH (Figure 3A).
Rats were similarly protected when treatment with Lenti-
CTRP3 also caused a significant reduction in BBB permeability
(Figure 3B).
Effect of CTRP3 on the Hematoma
Volume-Hemoglobin Assay
Neither recombinant nor lentivirus CTRP3 treatment had any
obvious effect on hemorrhage volume at 7 days (data not shown).
CTRP3 Promotes Angiogenesis and
Activates the AMPK/HIF-1α/VEGF Axis in
the ICH Brain
Angiogenesis is a vital part in beginning brain recovery
after ICH. Having shown CTRP3 as an innovative adipokine
involved in recovery following ICH, we assessed angiogenic
effects of CTRP3. As illustrated in Figures 4A,B, CTRP3
treatment significantly enhanced the amount of CD31-
positive capillary vessels in the zone bordering the
hematoma 7 days after ICH, pointing to the observation
that CTRP3 encourages vessel formation following
ICH.
To further figure out the signaling pathways in charge of
increased angiogenesis after CTRP3 treatment, many critical
mediators and cytokines required for angiogenesis were tested.
rCTRP3 significantly enhanced AMPK phosphorylation and
increased HIF-1α and VEGF expression (Figures 5A–E).
Similar changes in mediator and cytokine expression
were found when animals were treated with lentivirus
CTRP3 (Figures 5F–J). The results from qRT-PCR were
in agreement with those from Western blots (Figure 6).
These outcomes imply that CTRP3 promotes angiogenesis
after ICH possibly through the AMPK/HIF-1α/VEGF
axis.
Inhibiting AMKP or VEGF Activation
Attenuated Effects of Recombinant CTRP3
To determine whether the AMPK/HIF-1α/VEGF signaling
pathway is accountable for CTRP3 protection seen in
vivo, Com.C (AMPK axis inhibitor) or CBO-P11 (VEGF
inhibitor) was given together with rCTRP3 via the right lateral
cerebral ventricle, and neurological function, BBB integrity
and capillary density were assessed 7 days after ICH. As
shown in Figures 7A–D, blocking AMPK activation abolished
rCTRP3-induced pAMPK, HIF-1α and VEGF upregulation,
and blocking VEGF activation only abolished rCTRP3-induced
VEGF upregulation. In addition, CTRP3-induced capillary
formation was entirely terminated when either AMPK or
VEGF was inhibited (Figures 7G,H). But, the neurological
FIGURE 6 | Quantitative RT-PCR analysis of HIF-1α and VEGF-A mRNA
levels in the hematoma border zone 7 days after ICH. (A–C) Quantitative
RT-PCR analysis of the effect of rCTRP3 on CTRP3, HIF-1α and VEGF-A
mRNA levels. (D–F) Quantitative RT-PCR analysis of the effect of rCTRP3 on
CTRP3, HIF-1α and VEGF-A mRNA levels. Values are mean ± SEM. n = 4–6
per group. ∗p < 0.05 vs. sham; ∗∗p < 0.01 vs. sham; ##p < 0.01 vs. vehicle
or Lenti.null. CTRP3, C1q/tumor necrosis factor-related protein-3; rCTRP3,
recombinant CTRP3; Lenti.CTRP3, Lentivirus overexpression of CTRP3;
ICH, intracerebral hemorrhage.
protective aspect of CTRP3 was completely blocked by
Com.C and partially blocked by CBO-P11 (Figures 7E,F).
These results imply that, though the neurological protective
effect of CTRP3 is controlled significantly by AMPK/HIF-
1α/VEGF signaling-induced angiogenesis, other mechanisms
also provide neurological protection to CTRP3 against
ICH.
DISCUSSION
In the present study, we investigated the ability of CTRP3
to ameliorate secondary brain injury after ICH in rats. Based
on our knowledge, this is the first report that investigated
the effects of CTRP3 therapy in angiogenesis and brain
injury after ICH. The main discoveries of the study are as
follows: (1) exogenous rCTRP3 or Lenti-CTRP3 in ICH rats
demonstrates the same tendency to attenuate ICH-induced brain
injury; (2) CTRP3 promotes focal angiogenesis and attenuates
ICH-induced brain edema and breakdown of the BBB; and (3)
CTRP3 may exert its angiogenic effect through AMPK/HIF-
1α/VEGF signaling. These findings imply that CTRP3 is a novel
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FIGURE 7 | CTRP3 promotes angiogenesis via an AMPK-dependent signaling mechanism. (A) Western blot analysis of the effects of COM.C and CBO on
rCTRP3-induced p-AMPK, HIF-1α and VEGF-A expression. (B–D) Representative ratios of p-AMPK, HIF-1α and VEGF-A protein expression. (E) Modified Garcia test
analysis of the effects of COM.C and CBO on neurological function improvement induced by rCTRP3. (F) Evans blue dye extravasation analysis of the effects of
COM.C and CBO on ICH-induced BBB damage reduced by rCTRP3. (G) Immunohistochemical staining analysis of the effects of COM.C and CBO on angiogenesis
induced by rCTRP3. Capillary density measured by immunohistochemical staining for CD31 (brown) in the perifocal region in ICH (a), rCTRP3 (b), COM.C (c) and
CBO (d) 7 days after ICH. (H) Bar graph showing the number of brown stained capillaries. Values are mean ± SEM. n = 4–6 per group. ∗∗p < 0.01 vs. ICH;
#p < 0.05 vs. rCTRP3; ##p < 0.01 vs. rCTRP3; &p < 0.05 vs. COM.C. CTRP3, C1q/tumor necrosis factor-related protein-3; rCTRP3, recombinant CTRP3;
Lenti-CTRP3, Lentivirus overexpression of CTRP3; ICH, intracerebral hemorrhage; COM.C, compound C; CBO, CBO-P11.
angiogenic factor that might perform a key part in encouraging
angiogenesis by activating the AMPK signaling pathway during
ICH.
The prognosis of ICH is affected by multiple factors (Brown
et al., 1996). Neurotrophin family, anti-oxidative mediators,
anti-mitochondrial impairment or anti-inflammatory drugs
contribute to functional recovery and promote neuronal survival
in the central nervous system (Ip et al., 1993; Chung et al.,
2013; Xu et al., 2013; Chen et al., 2015; Wei et al., 2015).
Angiogenesis induced in the ischemic penumbra (Risau, 1997)
as well as rapid recovery of reperfusion and oxygen supply
in injured brain tissues are critical prognostic factors (Mayer
et al., 1998). In this study, we provide new evidence that
CTRP3 has strong angiogenic and neuroprotective aspects,
implying that CTRP3 could be an innovative therapeutic target
of ICH.
It is known that compensatory angiogenesis can happen in
the peri-hematoma region after ICH. Angiogenesis is a stepwise
procedure that includes an increase in vascular permeability,
degradation of the surrounding matrix, proliferation and
migration of endothelial cells, and stabilization of freshly created
microvessels (Conway et al., 2001). Concerted actions of many
angiogenic molecules are necessary in this procedure, and
VEGF is the most vital factor during each step of angiogenesis
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(Rosenstein et al., 1998; Yancopoulos et al., 2000). A number
of animal experimental studies have shown that VEGF and
fibroblast growth factor treatment encourages angiogenesis with
ideal efficacy and increases capillary numbers (Lavu et al.,
2011; Ye, 2016). However, endogenous angiogenesis following
a stroke is insufficient to reverse brain injury. Our study
shows that CTRP3 successfully encourages angiogenesis and
upregulates VEGF expression in the striatum ipsilateral to the
hemorrhage, which leads to increased vessel density. Because
CTRP3 has been established to directly encourage endothelial
cell proliferation and migration but not increase tube formation
(a procedure that requires complexity surpassing proliferation
and migration), angiogenic factors other than VEGF are likely
involved.
These findings contribute to the increasing literature on
the vital part of VEGF in brain injury. In fact, VEGF levels
are increased during a plethora of pathological events in the
brain, implicating its essential role in brain repair processes
(Cristofaro and Emanueli, 2009). VEGF binds to two receptors,
VEGF receptor-1 (VEGFR-1) and VEGF receptor-2 (VEGFR-
2), through which it encourages revascularization and the
mending of the BBB and re-establishes metabolic and trophic
assistance to injured tissue (Krum et al., 2008; Shimotake et al.,
2010). Future work in this field should aim to illuminate
whether CTRP3 interacts with one or both receptors during
ICH.
Because ICH-induced stress can change the composition,
structure and distribution of the extracellular matrix, which has
a vital role in creating normal brain tissue structures and is
closely linked with brain injury-induced brain edema formation
(Keep et al., 2012; Chung et al., 2013; Turner and Sharp,
2016), we investigated the effect of CTRP3 on BBB integrity
by measuring brain water content and extravasation of Evans
blue dye. We showed that angiogenesis via CTRP3 treatment
resulted in preservation of the BBB. This observation in ICH
extends past discoveries from other models of brain injury.
In a model of cerebral ischemia, VEGF bound to VEGFR-2,
which is expressed predominantly on activated astrocytes in the
central nervous system, and encouraged revascularization and
repair of the BBB by giving metabolic and trophic assistance
to injured tissue (Krum et al., 2008; Shimotake et al., 2010;
Hao et al., 2011). In a rat model of stroke, VEGF enhanced
angiogenesis in the ischemic brain and reduced neurological
deficits during recovery (Zhang et al., 2000). But, we were not
able to demonstrate any effect of CTRP3 treatment on hematoma
volume. We speculate that this may be due to use of a blood-
induced ICH model.
It is important to note that the CTRP3-treated rats manifested
not only greatly strengthened angiogenesis and enhanced BBB
preservation but also diminished neurological deficits. There
are several possibilities for this improvement. First, the great
angiogenic effect of CTRP3 in the border zone may help
in restoring the blood flow, thereby rescuing dying neurons
around the hematoma. Second, angiogenesis may assist new
neurons migrating to damaged brain regions and give trophic
material to these cells (Kojima et al., 2010; Lei et al., 2013).
Finally, CTRP3 may promote differentiation of neural stem
cells into neurons. Such intriguing possibilities all merit express
study.
Around the hematoma, ischemia and hypoxia are apparent
in ICH and this stress activates the AMPK and HIF1 signaling
pathway, which induces the AMPK phosphorylation in human
umbilical vein endothelial cells and promotes the recruitment,
migration, proliferation and differentiation of endothelial cells
(Nagata et al., 2003). In ischemic mice hindlimbs, AICAR,
an AMPK antagonist induces expression of endogenous HIF
target gene VEGF, but dominant-negative AMPK abolishes this
expression at both steady state mRNA and protein levels (Ouchi
et al., 2005). These data suggest that AMPK signaling is likely to
regulate the expression of VEGF and promote angiogenesis in
response to ischemic injury.
CTRP3 is a paralog of adiponectin, and it is well received
that adiponectin encourages angiogenesis through activation of
AMPK signaling (Shimano et al., 2010). Yet, whether CTRP3
encourages angiogenesis in cerebral tissue through the same
pathway is not yet known. More important, inhibiting AMPK
phosphorylation by Com.C greatly eradicated CTRP3-induced
HIF-1α and VEGF expression and blocked the angiogenic effect
of CTRP3. These findings defend the existence of an AMPK-
dependent mechanism for angiogenic effects of CTRP3.
CONCLUSION
We conclude that CTRP3, a key member of a newly identified
adipokine family, upregulates expression of angiogenic cytokines
and induces robust angiogenesis, which led to enhanced
preservation of the BBB and reduction of neurological deficits
after ICH. The effect is mediated by the AMPK signaling
pathway. These findings suggest that CTRP3 plays a positive role
during ICH and has therapeutic potential.
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